弥漫大B细胞淋巴瘤的基因分型进展
Progress on Genotyping of Diffuse Large B-Cell Lymphoma
摘要: 弥漫大B细胞淋巴瘤(Diffuse Large B-cell Lymphoma, DLBCL)是血液系统恶性肿瘤，具有高度异质性，R-CHOP方案作为一线治疗方案，已不能满足临床需求，随着基因检测技术的飞快进展，探讨DLBCL在分子遗传学方面的异常成为可能，基于基因异常变化的基因亚型分型被人们熟知，也为个体化治疗及靶向药物研究提供更多参考依据。本文就目前最新的DLBCL基因分型进行论述。
Abstract: Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor of hematological system, which is highly heterogeneous. R-CHOP regimen can no longer be clinically needed as a first-line treatment regimen. With the rapid development of gene detection technology, it is possible to explore the mo-lecular genetic abnormalities of DLBCL. Genotyping based on abnormal gene changes is well known and provides more reference for individualized therapy and targeted drug research. In this paper, the latest genotyping of DLBCL is discussed.
文章引用：李小凡, 郭新红. 弥漫大B细胞淋巴瘤的基因分型进展[J]. 临床医学进展, 2023, 13(12): 19238-19243. https://doi.org/10.12677/ACM.2023.13122708

参考文献

[1] Sehn, L.H. and Salles, G. (2021) Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 384, 842-858. [Google Scholar] [CrossRef] 
[2] Campo, E., Jaffe, E.S., Cook, J.R., et al. (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood, 140, 1229-1253.
[3] 王艳君, 孟丹. 弥漫大B细胞淋巴瘤异质性研究进展[J]. 中国肿瘤临床与康复, 2009, 16(5): 455-457.
[4] Pfreundschuh, M., Schubert, J., Ziepert, M., et al. (2008) Six versus Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab in Elderly Patients with Aggressive CD20 + B Cell Lymphomas: A Randomised Controlled Trial (RICOVER-60). The Lancet Oncology, 9, 105-116. [Google Scholar] [CrossRef] 
[5] Ennishi, D., His, E.D., Steidl, C., et al. (2020) Toward a New Molecular Taxonomy of Diffuse Large B-Cell Lymphoma. Cancer Discovery, 9, 1267-1281. [Google Scholar] [CrossRef] 
[6] Epperla, N., Vaughn, J.L., Othus, M., et al. (2020) Recent Survival Trends in Diffuse Large B-Cell Lymphoma—Have We Made Any Progress beyond Rituximab. Cancer Medi-cine, 9, 5519-5525. [Google Scholar] [CrossRef] [PubMed]
[7] 杨漾, 张义成. 自体造血干细胞移植及CAR-T细胞疗法在复发/难治弥漫性大B细胞淋巴瘤中的应用进展[J]. 临床血液学杂志, 2023, 36(9): 622-626. [Google Scholar] [CrossRef] 
[8] Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gas-coyne, R.D., Delabie, J., Ott, G., et al. (2004) Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. Blood, 103, 275-282. [Google Scholar] [CrossRef] [PubMed]
[9] Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Pat-more, R., Roman, E. and Jack, A. (2010) Rearrangement of MYC Is Associated with Poor Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab. Journal of Clinical Oncology, 28, 3360-3365. [Google Scholar] [CrossRef] 
[10] Rosenthal, A. and Younes, A. (2017) High Grade B-Cell Lym-phoma with Rearrangements of MYC and BCL2 and/or BCL6: Double Hit and Triple Hit Lymphomas and Double Ex-pressing Lymphoma. Blood Reviews, 31, 37-42. [Google Scholar] [CrossRef] [PubMed]
[11] Dent, A.L., Vasanwala, F.H. and Toney, L.M. (2002) Regulation of Gene Expression by the Proto-Oncogene BCL-6. Critical Reviews in Oncology/Hematology, 41, 1-9. [Google Scholar] [CrossRef] 
[12] Beaulieu, M.E., Castillo, F. and Soucek, L. (2020) Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells, 9, Article No. 1038. [Google Scholar] [CrossRef] [PubMed]
[13] Wei, M.C. (2004) Bcl-2-Related Genes in Lymphoid Neoplasia. Interna-tional Journal of Hematology, 80, 205-209. [Google Scholar] [CrossRef] 
[14] Leeman-Neill, R.J. and Bhagat, G. (2018) BCL6 as a Therapeutic Target for Lymphoma. Expert Opinion on Therapeutic Targets, 22, 143-152. [Google Scholar] [CrossRef] [PubMed]
[15] 钟幸, 余娜莎, 刘志良, 等. “双表达”与“双打击”淋巴瘤临床特征、生存及预后因素分析[J]. 实用癌症杂志, 2022, 37(1): 150-153.
[16] 许彭鹏, 赵维莅. 中国临床肿瘤学会淋巴瘤诊疗指南解读之弥漫性大B细胞淋巴瘤的规范治疗[J]. 华西医学, 2019, 34(4): 351-354.
[17] Duffy, M.J., O’Grady, S., Tang, M. and Crown, J. (2021) MYC as a Target for Cancer Treatment. Cancer Treatment Reviews, 94, Article ID: 102154. [Google Scholar] [CrossRef] [PubMed]
[18] 张炜, 沈克锋, 张美兰, 等. 中国人群中弥漫性大B细胞淋巴瘤基于基因变异的分型及其预后意义[J]. 内科急危重症杂志, 2022, 28(3): 186-190.
[19] Rosenwald, A., Wright, G., Chan, W.C., et al. (2002) The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. The New England Journal of Medicine, 346, 1937-1947. [Google Scholar] [CrossRef] 
[20] 沈昊, 李超群, 郭玉娇, 等. 伊布替尼治疗B细胞恶性肿瘤的疗效和安全的单臂Meta分析[J]. 药学与临床研究, 2022, 30(5): 434-440. [Google Scholar] [CrossRef] 
[21] 王根, 李红红. 伊布替尼联合R-CHOP化疗方案在弥漫大B细胞淋巴瘤治疗中的临床效果分析[J]. 名医, 2022(13): 165-167.
[22] Seshadri, M.R. and Melnick, A.M. (2022) Targeting MALT1 for the Treatment of Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma, 63, 789-798. [Google Scholar] [CrossRef] [PubMed]
[23] Schmitz, R., Wright, G.W., Huang, D.W., Johnson, C.A., Phelan, J.D., Wang, J.Q., et al. (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 378, 1396-1407. [Google Scholar] [CrossRef] 
[24] 徐卫, 梁金花. 弥漫大B细胞淋巴瘤新基因分型及分子靶向的治疗进展[J]. 临床血液学杂志, 2020, 33(9): 594-598. [Google Scholar] [CrossRef] 
[25] Chapuy, B., Stewart, C., Dunford, A.J., Kim, J., Kamburov, A., Redd, R.A., et al. (2018) Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes. Nature Medicine, 24, 679-690. [Google Scholar] [CrossRef] [PubMed]
[26] Wright, G.W., Huang, D.W., Phelan, J.D., Coulibaly, Z.A., Roulland, S., Young, R.M., et al. (2020) A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell, 37, 551-568.e14. [Google Scholar] [CrossRef] [PubMed]
[27] 赵凯祺, 苏丽萍. MICM分型在弥漫大B细胞淋巴瘤中的作用研究进展[J]. 陕西医学杂志, 2023, 52(9): 1275-1278.
[28] Lacy, S.E., Barrans, S.L., Beer, P.A., Painter, D., Smith, A.G., Roman, E., et al. (2020) Targeted Sequencing in DLBCL, Molecular Subtypes, and Outcomes: A Haematological Malignancy Research Network Report. Blood, 135, 1759-1771. [Google Scholar] [CrossRef] [PubMed]
[29] Liang, X.J., Song, X.Y., Wu, J.L., Liu, D., Lin, B.Y., Zhou, H.S. and Wang, L. (2022) Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma. International Journal of Biological Sciences, 18, 1313-1327. [Google Scholar] [CrossRef] [PubMed]
[30] Grommes, C., Pastore, A., Palaskas, N., Tang, S.S., Campos, C., Schartz, D., et al. (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Dis-covery, 7, 1018-1029. [Google Scholar] [CrossRef] 
[31] Ling, Y., Tao, M.X., De, Y.W., et al. (2023) Structural Clas-sification of EZH2 Inhibitors and Prospects for the Treatment of Tumor: A Review. Medicinal Chemistry Research, 32, 1589-1604. [Google Scholar] [CrossRef] 
[32] 李佳苗, 曹小梅, 李冬菊, 等. 18F-FDG PET/CT扩散参数联合肿瘤代谢体积评估弥漫大B细胞淋巴瘤患者预后[J/OL]. 中国医学影像技术, 2023: 1-9. http://kns.cnki.net/kcms/detail/11.1881.R.20230926.1417.026.html

为你推荐